The head of Google DeepMind believed its drug discovery spinout would halve the time taken to find new medicines, attracting the attention of the world’s biggest pharmaceutical companies which are looking to artificial intelligence to revolutionise the lengthy process.
Speaking to the Financial Times, Demis Hassabis, who co-founded Google’s AI unit and also leads the drugs offshoot Isomorphic Labs, said the goal was to reduce the discovery stage — when potential drugs are identified before clinical trials — from the average of five years to two. “I think that would be success for us and be very meaningful,” he said.
您已閱讀16%（773字），剩余84%（4197字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。